NASDAQ · TOI
The Oncology Institute, Inc.
$5.13-$1.26 (-19.72%)
The Oncology Institute, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.23% below the high.
Loading market information…
NASDAQ · MGRX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Mangoceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Mangoceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.13-$1.26 (-19.72%)
The Oncology Institute, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.23% below the high.
$1.19$0.00 (0.0%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.39% below the high.
$5.19-$0.06 (-1.14%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.35% below the high.
$2.85-$0.15 (-5.0%)
Entero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.2% below the high.
$1.36-$0.06 (-3.9%)
Femasys Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.9% below the high.
$6.30-$0.13 (-2.02%)
Healthcare Triangle, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
$0.11+$0.01 (+10.0%)
CASI Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.86% below the high.
$0.41$0.00 (0.0%)
Clearside Biomedical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.6% below the high.
